Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Intra-Cellular Therapies stock

Own Intra-Cellular Therapies stock in just a few minutes.


Fact checked

Intra-Cellular Therapies, Inc is a biotechnology business based in the US. Intra-Cellular Therapies shares (ITCI) are listed on the NASDAQ and all prices are listed in US Dollars. Intra-Cellular Therapies employs 330 staff and has a trailing 12-month revenue of around USD$3.1 million.

How to buy shares in Intra-Cellular Therapies

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Intra-Cellular Therapies. Find the stock by name or ticker symbol: ITCI. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Intra-Cellular Therapies reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Intra-Cellular Therapies, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Intra-Cellular Therapies. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Intra-Cellular Therapies share price

Use our graph to track the performance of ITCI stocks over time.

Intra-Cellular Therapies shares at a glance

Information last updated 2020-10-20.
52-week range USD$8.27 - USD$43.56
50-day moving average USD$25.9766
200-day moving average USD$21.9889
Wall St. target price USD$54.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.814

Buy Intra-Cellular Therapies shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Intra-Cellular Therapies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Intra-Cellular Therapies financials

Revenue TTM USD$3.1 million
Gross profit TTM USD$-89,064,225
Return on assets TTM -31.98%
Return on equity TTM -58.64%
Profit margin 0%
Book value $5.683
Market capitalisation USD$2.1 billion

TTM: trailing 12 months

Shorting Intra-Cellular Therapies shares

There are currently 5.9 million Intra-Cellular Therapies shares held short by investors – that's known as Intra-Cellular Therapies's "short interest". This figure is 12.9% down from 6.7 million last month.

There are a few different ways that this level of interest in shorting Intra-Cellular Therapies shares can be evaluated.

Intra-Cellular Therapies's "short interest ratio" (SIR)

Intra-Cellular Therapies's "short interest ratio" (SIR) is the quantity of Intra-Cellular Therapies shares currently shorted divided by the average quantity of Intra-Cellular Therapies shares traded daily (recently around 4.1 million). Intra-Cellular Therapies's SIR currently stands at 1.44. In other words for every 100,000 Intra-Cellular Therapies shares traded daily on the market, roughly 1440 shares are currently held short.

However Intra-Cellular Therapies's short interest can also be evaluated against the total number of Intra-Cellular Therapies shares, or, against the total number of tradable Intra-Cellular Therapies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intra-Cellular Therapies's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Intra-Cellular Therapies shares in existence, roughly 70 shares are currently held short) or 0.0835% of the tradable shares (for every 100,000 tradable Intra-Cellular Therapies shares, roughly 84 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Intra-Cellular Therapies.

Find out more about how you can short Intra-Cellular Therapies stock.

Intra-Cellular Therapies share dividends

We're not expecting Intra-Cellular Therapies to pay a dividend over the next 12 months.

Intra-Cellular Therapies share price volatility

Over the last 12 months, Intra-Cellular Therapies's shares have ranged in value from as little as $8.27 up to $43.56. A popular way to gauge a stock's volatility is its "beta".

ITCI.US volatility(beta: 1.64)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intra-Cellular Therapies's is 1.6387. This would suggest that Intra-Cellular Therapies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Intra-Cellular Therapies overview

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company is developing its lead drug candidate, CAPLYTA for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site